羟氯喹治疗不完全性狼疮的随机安慰剂对照试验
SMILE试验在不完全性狼疮(ILE)患者中比较羟氯喹与安慰剂,共187例随机、7个中心,分析180例(羟氯喹92例、安慰剂88例),24个月内两组达到SLICC分类标准或进展为SLE的比率相似(P=0.72和P=0.98),未显示羟氯喹对ILE进展的效应。
要点
- ILE定义为抗核抗体阳性加1至2条额外标准,15至49岁患者入组。
- 180例分析中55例出现额外标准,118例完成或退出者中24例(13.3%)进展为SLE。
- 两组达到SLICC标准和进展为SLE的比率相似(P=0.72和P=0.98)。
核心结论
- SMILE试验未显示羟氯喹对不完全性狼疮进展的效应,但结果提供了ILE人群SLE风险的见解。
研究设计与样本
- 随机、双盲、安慰剂对照试验,羟氯喹与安慰剂1:1随机,7个中心,187例随机,排除7例基线即符合SLE分类者后分析180例(羟氯喹92例、安慰剂88例)。
- ILE定义为抗核抗体阳性加1至2条额外2012年SLICC标准,患者15至49岁,每3个月评估一次共24个月,较早符合SLICC分类者退出。
主要发现
- 全部入组者中55例出现额外标准;118例早期退出或完成24个月评估者中,24例(13.3%)进展为SLE,另24例出现额外标准但未达分类。
- 两组达到SLICC标准和进展为SLE的比率相似(P=0.72和P=0.98)。
- SLE的发生与新发颧部皮疹、口腔溃疡、关节压痛或胸膜炎相关(P<0.04)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE. METHODS: Hydroxychloroquine (HCQ) was chosen as an ILE intervention for a randomized, double-blind trial to determine whether the rate of accumulation of SLE features defined by the 2012 Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) criteria could be reduced. ILE was defined as antinuclear antibody positivity with one to two additional criteria. Patients 15 to 49 years old were eligible. Randomization was 1:1 HCQ to placebo. Evaluations were at 3-month intervals over 24 months. Meeting SLICC classification sooner required exit. RESULTS: Participants (N = 187) were randomized at seven sites. After excluding 7 patients who met SLE classification at baseline when screening laboratory data were completed, 180 patients were analyzed: 92 receiving HCQ and 88 receiving placebo. Considering all these enrollees, 55 developed additional criteria. Of the 118 participants who exited early with SLE or who completed 24 months of evaluation, SLE classification developed in 24 (13.3%); another 24 developed additional criteria but did not meet classification. The rates of acquisition of SLICC criteria and progression to SLE were similar in the two groups (P = 0.72 and P = 0.98, respectively). Development of SLE was associated with new malar rash, oral ulcers, joint tenderness, or pleurisy (P < 0.04). CONCLUSION: Although the Study of Antimalarials in Incomplete Lupus Erythematosus (SMILE) did not show effects of HCQ on ILE progression, the results offer insights into SLE risk in the ILE population.
引用
- Olsen NJ, Liao D, James JA, et al. A Randomized, Placebo-Controlled Trial of Hydroxychloroquine in Incomplete Lupus. Arthritis Rheumatol. 2025. PMID: 40955637. doi:10.1002/art.43391
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。